DOCSLIB.ORG

Hypertension and the Prothrombotic State

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hypertension and the Prothrombotic State Journal of Human Hypertension (2000) 14, 687–690 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh REVIEW ARTICLE Hypertension and the prothrombotic state GYH Lip Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK The basic underlying pathophysiological processes related to conventional risk factors, target organ dam- underlying the major complications of hypertension age, complications and long-term prognosis, as well as (that is, heart attacks and strokes) are thrombogenesis different antihypertensive treatments. Further work is and atherogenesis. Indeed, despite the blood vessels needed to examine the mechanisms leading to this being exposed to high pressures in hypertension, the phenomenon, the potential prognostic and treatment complications of hypertension are paradoxically throm- implications, and the possible value of measuring these botic in nature rather than haemorrhagic. The evidence parameters in routine clinical practice. suggests that hypertension appears to confer a Journal of Human Hypertension (2000) 14, 687–690 prothrombotic or hypercoagulable state, which can be Keywords: hypercoagulable; prothrombotic; coagulation; haemorheology; prognosis Introduction Indeed, patients with hypertension are well-recog- nised to demonstrate abnormalities of each of these Hypertension is well-recognised to be an important 1 components of Virchow’s triad, leading to a contributor to heart attacks and stroke. Further- prothrombotic or hypercoagulable state.4 Further- more, effective antihypertensive therapy reduces more, the processes of thrombogenesis and athero- strokes by 30–40%, and coronary artery disease by 2 genesis are intimately related, and many of the basic approximately 25%. Nevertheless the basic under- concepts thrombogenesis can be applied to athero- lying pathophysiological processes underlying both genesis. Importantly, recent improvements in bio- of these major complications of hypertension are chemical techniques have enabled us to quantify dif- thrombogenesis and atherogenesis. Indeed, despite ferent components of both these processes. the blood vessels being exposed to high pressures in hypertension, the complications of hypertension are paradoxically thrombotic in nature rather than Evidence for the prothrombotic state in haemorrhagic. Whilst much attention has been hypertension focused on the renin-angiotensin system, cathechol- Evidence for the hypercoagulable state in hyperten- amines and other neurohormonal mechanisms sion has been extensively reviewed.4–6 Indeed, evi- involved in the pathogenesis of hypertension, the dence from numerous epidemiological,7–9 cross- study of the prothrombotic state in hypertension has sectional10,11 and cohort studies12,13 have reported been relatively neglected. abnormalities in the coagulation and fibrinolytic Over 150 years ago, Virchow postulated that three pathways, as well as in platelets and the endo- features predispose to thrombus formation, that is, thelium. abnormalities in blood flow, blood constituents and the vessel wall.3 Whilst Virchow was referring to venous thrombosis, the concepts can be applied to Relation to conventional risk factors arterial thrombosis. An update of Virchow’s triad for These abnormalities in haemostasis appear to be thrombogenesis for the new millennium can be con- additive to conventional risk factors for cardiovascu- sidered by reference to abnormalities of haemo- lar and cerebrovascular events. For example, in the rheology and turbulence at bifurcations and stenotic ECAT study, high plasma fibrinogen in association regions (that is, ‘abnormal blood flow’), abnormali- with high serum cholesterol was associated with the ties in platelets as well as the coagulation and highest risk for cardiovascular events.14 The inter- fibrinolytic pathways (‘abnormal blood con- action between plasma fibrinogen and cholesterol stituents’) and finally, abnormalities in the endo- 4 levels is also demonstrated in the Leigh Study, thelium (‘abnormal vessel wall’). where the incidence of heart attacks was six times greater in those with high plasma fibrinogen (у3.5 g/l) and cholesterol levels (у6.2 mmol/l), Correspondence: Dr GYH Lip, Haemostasis Thrombosis and when compared to those with low fibrinogen Vascular Biology Unit, University Department of Medicine, City Ͻ 15 Hospital, Birmingham B18 7QH, UK. ( 3.5 g/l) levels. Other risk factors, such as smok- E-mail: [email protected] ing and diabetes, markedly influence the prothrom- Received and accepted 18 March 2000 botic state and are probably additive to the intrinsic Hypertension and the prothrombotic state GYH Lip 688 abnormalities (and cardiovascular risk) seen in merely markers or consequences of atherothrom- hypertensives. botic disease, but may contribute to the pathogen- esis of hypertension and its complications. Indeed Association with target organ damage various indices are predictive of outcome in hyper- tension. The abnormalities in haemostasis in hypertensives For example the Leigh general practice study can be related to target organ damage, such as the reported that hypertensive subjects with plasma presence of left ventricular hypertrophy on echocar- Ͼ 10 fibrinogen levels 3.5 g/l had a 12-fold higher car- diography. The latter is a powerful predictor of diovascular risk than those with plasma fibrinogen cardiovascular events, with an eight-fold increase in levels Ͻ2.9 g/l.15 Blann et al26 suggested that high the risk of stroke and a four-fold increase in the risk von Willebrand factor levels had prognostic value of coronary artery disease. The presence of left ven- in hypertension, being predictive of cardiovascular tricular hypertrophy (LVH) is also an independent disease progression. The study by Agewall et al12 contributor to the risk of stroke in atrial fibril- + 16 found that prothrombin fragment 1 2 and C-reactive lation. Furthermore, high von Willebrand factor protein were independent predictors of major coron- levels, an established index of endothelial damage ary events. Our recent study also suggested that or dysfunction can be related to microalbuminuria patients with hypertension who developed cardio- (defined as the excretion of urine albumin between vascular or cerebrovascular events at 4 years’ follow- 20 and 200 mcg/min), another surrogate manifes- 17 up had higher baseline vWf and fibrin D-dimer lev- tation of hypertensive target organ damage. els compared to those without events, although on The abnormalities in various indices can perhaps Cox multivariate proportional hazards analysis only be related to the degree, and possibly the duration plasma fibrinogen and blood pressure levels of hypertension, and those with mild hypertension emerged as independent predictors.13 or lower blood pressures, and more recent onset The possibility therefore remains that some hypertension (which is usually more difficult to pre- prothrombotic indices, either individually or combi- cisely quantify) may show less abnormalities in the nation, may provide sufficiently high predictive prothrombotic state. For example, patients with Ͼ value for cardiovascular disease and stroke. Further severe hypertension (defined as 160/95 mm Hg) prospective studies on large cohorts would be demonstrate high plasma von Willebrand factor required to confirm this hypothesis. levels10,18 which does not appear to be present in patients with milder elevations of blood pressure.7,8 Although endothelial dysfunction or damage can be Effects of treatment present as a result of hypertension, others have even Treating hypertension may reduce the prothrom- considered that endothelial damage may actually 19 botic state. Indeed, antihypertensive agents with promote hypertension. particular benefits in the hypercoagulable state in hypertensives would be likely to have additional Association with the complications of advantages in reducing stroke and other throm- hypertension boembolic events. For example, treated hyperten- sives demonstrate normal von Willebrand factor The common complications of hypertension can 18 also be related to a prothrombotic state. For levels. However, different drugs may affect the prothrombotic state differently (as reviewed by example, hypertension is a common cause of atrial 6 fibrillation20 and indeed, is additive to the risk of Lee ). For example, drugs such as beta-blockers or stroke and thromboembolism with this arrhyth- calcium antagonists may have favourable haemo- 21 rheological actions. In contrast, diuretics may have mia. Atrial fibrillation per se is also well-recog- 27,28 nised to be associated with abnormalities of haemo- the opposite effect in increasing blood viscosity. stasis and endothelial dysfunction, which are These differences may in part explain some of the altered by cardioversion and antithrombotic ther- differences between different antihypertensive apy, and are independent of underlying aetiology or agents in the reduction of endpoints in some trials structural heart disease.22 of antihypertensive therapy. For example, thiazides Hypertension is an important cause of heart fail- are beneficial in older hypertensives (over beta- 23 blockers and placebo) in reducing stroke and cardiac ure and the evidence also points towards a hyper- 29,30 coagulable state in heart failure.24 Indeed, heart fail- events. In contrast, hypertensive patients on ure is an important contributor to stroke and diuretic therapy have an increased mortality if elec- trocardiographic abnormalities (including
Load more

Recommended publications
  • High B1a0d Pressure and Its Treatment in General
    HIGH B1A0D PRESSURE AND ITS TREATMENT IN GENERAL PRACTICE WITH PARTICULAR REFERENCE TO A SERIES OF 100 CASES TREATED BY THE AUTHOR By HAROLD WILSON B01YBR IB.ffh.B. ProQuest Number: 13849841 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13849841 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 -CONTENTS SECTION 1. Introduction. SECTION 2. General Remarks. Definitions of General Interest. Present Views on Etiology. Pathology and Morbid Anatomy. Brief Historical Survey. SECTION 3. The Present Position. Prevalence. Clinical Manifestations. Prognosis. SECTION 4. Prevalence in Bolton. Summary of Cases. Symptomatology and Case Histories Prognosis. Treatment. SECTION 5. Conclusions. Bibliography. SECTION 1. INTRODUCTION. I think it can truthfully be said that the most interest­ ing problems in Medioine are those that are most baffling. Some years ago Ralph M a j o r ^ wrote these words, ”If our knowledge of the etiology of arterial hypertension is shrouded in a oertain haze, our knowledge of an effective therapy in this disease is enveloped in a dense fog.n A study of some of the vast literature on this subject does not greatly clarify the obscurity.
    [Show full text]
  • 441.2.Full.Pdf
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2018-eular.4790 on 12 June 2018. Downloaded from Scientific Abstracts Thursday, 14 June 2018 441 All GCA TAK p (n 23) (n 13) (n 8) Female, n (%) 19 (82.6) 12 (92.3) 6 (75) ns Age at diagnosis 63 (51–68) 68 (63–73) 43.5 (30.5–57) 0.003 Diagnostic latency (months) 4.5 (2–12) 3 (2–10) 8 (3.5–12) ns ESR at disease onset (mm/h) 49 (38–68) 52.5 (45.5– 42 (40–61.5) ns 59.7) CRP at disease onset (mg/L) 61.8 (13– 89 (32.5–106) 60.5 (9.3–132.5) ns 132.5) Disease duration at PET/MR 27 (18–36) 24 (13–29.5) 36.5 (14.75– ns (months) 129.3) ESR at examination (mm/h) 18 (9–35) 16 (7–31) 20.5 (11–44.5) ns CRP at examination (mg/L) 4.5 (2.55–8.9) 3.9 (3.48–4.72) 4.55 (2.05–10.4) ns Results: 23 LVV patients were included, 56.5% GCA, 34.8% TAK and 8.7% iso- Results: Among 602 patients with TA during this period, 119 (19.8%) were jTA, lated aortitis, all Caucasian, mostly females (82%). We considered 55 PET scans, while 483 were aTA. Female predominance was less striking in jTA (71.4%) than 32/55 in LVV group (from min. 1 to max. 3 scans/patient) mainly during follow-up aTA (79%), p=0.047. Patients with jTA had presented more commonly with fever (29/32 scans), and 23/55 in control group.
    [Show full text]
  • Echocardiography in Pediatric Pulmonary Hypertension
    REVIEW ARTICLE published: 12 November 2014 PEDIATRICS doi: 10.3389/fped.2014.00124 Echocardiography in pediatric pulmonary hypertension Pei-Ni Jone* and D. Dunbar Ivy Pediatric Cardiology, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA Edited by: Pulmonary hypertension (PH) can be a rapidly progressive and fatal disease. Although Antonio Francesco Corno, Universiti right heart catheterization remains the gold standard in evaluation of PH, echocardiogra- Sains Malaysia, Malaysia phy remains an important tool in screening, diagnosing, evaluating, and following these Reviewed by: Jeffrey Feinstein, Stanford University, patients. In this article, we will review the important echocardiographic parameters of the USA right heart in evaluating its anatomy, hemodynamic assessment, systolic, and diastolic Cecile Tissot, The University function in children with PH. Children’s Hospital, Switzerland Tilman Humpl, SickKids Hospital, Keywords: pediatric pulmonary hypertension, echocardiography, right heart, right ventricular function Canada *Correspondence: Pei-Ni Jone, Pediatric Cardiology, Children’s Hospital Colorado, University of Colorado School of Medicine, 13123 East 16th Avenue, B100, Aurora, CO 80045, USA e-mail: pei-ni.jone@ childrenscolorado.org INTRODUCTION of the RA area in end-systole is performed to evaluate for RA dila- Pulmonary hypertension (PH) is a progressive disease that carries tion (Figure 1)(3). Indexed RA area to body surface area in adult high morbidity and mortality. Although cardiac catheterization is patients with idiopathic PH has been a predictor of mortality and used to define PH, echocardiography is the most important non- has been shown to be a prognostic marker for follow up of PH invasive tool that is used to detect PH (1).
    [Show full text]
  • What Is Dvt? Deep Vein Thrombosis (DVT) Occurs When an Abnormal Blood Clot Forms in a Large Vein
    What is DVt? Deep vein thrombosis (DVT) occurs when an abnormal blood clot forms in a large vein. These clots usually develop in the lower leg, thigh, or pelvis, but can also occur in other large veins in the body. If you develop DVT and it is diagnosed correctly and quickly, it can be treated. However, many people do not know if they are at risk, don’t know the symptoms, and delay seeing a healthcare professional if they do have symptoms. CAn DVt hAppen to me? Anyone may be at risk for DVT but the more risk factors you have, the greater your chances are of developing DVT. Knowing your risk factors can help you prevent DVt: n Hospitalization for a medical illness n Recent major surgery or injury n Personal history of a clotting disorder or previous DVT n Increasing age this is serious n Cancer and cancer treatments n Pregnancy and the first 6 weeks after delivery n Hormone replacement therapy or birth control products n Family history of DVT n Extended bed rest n Obesity n Smoking n Prolonged sitting when traveling (longer than 6 to 8 hours) DVt symptoms AnD signs: the following are the most common and usually occur in the affected limb: n Recent swelling of the limb n Unexplained pain or tenderness n Skin that may be warm to the touch n Redness of the skin Since the symptoms of DVT can be similar to other conditions, like a pulled muscle, this often leads to a delay in diagnosis. Some people with DVT may have no symptoms at all.
    [Show full text]
  • A 12-Years Rectal Bleeding Complicated with Deep Vein Thrombosis, Is Hemorrhoid the Real Cause?
    Case Report Clinical Case Reports Volume 10:11, 2020 DOI: 10.37421/jccr.2020.10.1395 ISSN: 2165-7920 Open Access A 12-Years Rectal Bleeding Complicated with Deep Vein Thrombosis, Is Hemorrhoid the Real Cause? Yi-Qun Zhang, Meng Niu and Chun-Xiao Chen* Department of Gastroenterology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P. R. China Abstract Colorectal venous malformation is a rare condition that can cause massive rectal bleeding. This is the first report of colorectal venous malformation complicated with massive bleeding and lowers limb deep vein thrombosis, and the two life-threatening conditions were both treated successfully. Keywords: Colorectal venous malformation • Rectal bleeding • Sclerotherapy • Deep vein thrombosis Introduction A 16-year-old man presented to the clinic with long-standing recurrent hematochezia and profound anemia. Per the mother, his rectal bleeding was first noticed around the age of 4 with one episode per 2-3 months that was diagnosed as hemorrhoids without specific treatment. It had worsened for 2 months with progression to 1 bloody bowel movement daily. He had no family history of hematologic disorders or vascular anomalies. The patient had accepted 600 ml red-blood cell perfusion and intravenous sucrose-iron transfusions for severe anemia with hemoglobin 5.8 g/dL, hematocrit 25.9% and MCV 69.7 fL at local hospital. Case Report Upon admission, the patient’s vital signs were within normal limits. His abdomen was supple and without tenderness. Digital rectal examination confirmed partially thrombosed, circumferential mixed hemorrhoids. Laboratory tests revealed a hemoglobin 8.0 g/L and D-dimer 15760 g/L.
    [Show full text]
  • Effects of Immediate Versus Delayed Antihypertensive Therapy on Outcome in the Systolic Hypertension in Europe Trial Jan A
    Original article 847 Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial Jan A. Staessena, Lutgarde Thijsa, Robert Fagarda, Hilde Celisa, Willem H. Birkenha¨gerb, Christopher J. Bulpittc, Peter W. de Leeuwd, Astrid E. Fletchere, Franc¸oise Forettef, Gastone Leonettig, Patricia McCormackh, Choudomir Nachevi, Eoin O’Brienh, Jose´ L. Rodicioj, Joseph Rosenfeldk, Cinzia Sartil, Jaakko Tuomilehtol, John Websterm, Yair Yodfatn and Alberto Zanchettig, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Background To assess the impact of immediate versus systolic hypertension. Immediate compared with delayed delayed antihypertensive treatment on the outcome of treatment prevented 17 strokes or 25 major cardiovascular older patients with isolated systolic hypertension, we events per 1000 patients followed up for 6 years. These extended the double-blind placebo-controlled Systolic findings underscore the necessity of early treatment of Hypertension in Europe (Syst-Eur) trial by an open-label isolated systolic hypertension. J Hypertens 22:847–857 & follow-up study lasting 4 years. 2004 Lippincott Williams & Wilkins. Methods The Syst-Eur trial included 4695 randomized Journal of Hypertension 2004, 22:847–857 patients with minimum age of 60 years and an untreated Keywords: calcium-channel blocker, clinical trial, isolated systolic blood pressure of 160–219 mmHg systolic and below hypertension, outcome, myocardial infarction, stroke 95 mmHg diastolic. The double-blind
    [Show full text]
  • Orthostatic Hypotension in a Cohort of Hypertensive Patients Referring to a Hypertension Clinic
    Journal of Human Hypertension (2015) 29, 599–603 © 2015 Macmillan Publishers Limited All rights reserved 0950-9240/15 www.nature.com/jhh ORIGINAL ARTICLE Orthostatic hypotension in a cohort of hypertensive patients referring to a hypertension clinic C Di Stefano, V Milazzo, S Totaro, G Sobrero, A Ravera, A Milan, S Maule and F Veglio The prevalence of orthostatic hypotension (OH) in hypertensive patients ranges from 3 to 26%. Drugs are a common cause of non-neurogenic OH. In the present study, we retrospectively evaluated the medical records of 9242 patients with essential hypertension referred to our Hypertension Unit. We analysed data on supine and standing blood pressure values, age, sex, severity of hypertension and therapeutic associations of drugs, commonly used in the treatment of hypertension. OH was present in 957 patients (10.4%). Drug combinations including α-blockers, centrally acting drugs, non-dihydropyridine calcium-channel blockers and diuretics were associated with OH. These pharmacological associations must be administered with caution, especially in hypertensive patients at high risk of OH (elderly or with severe and uncontrolled hypertension). Angiotensin-receptor blocker (ARB) seems to be not related with OH and may have a potential protective effect on the development of OH. Journal of Human Hypertension (2015) 29, 599–603; doi:10.1038/jhh.2014.130; published online 29 January 2015 INTRODUCTION stabilization, and then at 1 and 3 min after standing. The average of the Orthostatic hypotension (OH) is defined as the reduction in blood last two SBP and DBP values measured in the supine position and the pressure (BP) of at least 20 mmHg systolic and/or 10 mm Hg lowest value during standing were considered.
    [Show full text]
  • Thrombosis and Embolism After Injury J Clin Pathol: First Published As 10.1136/Jcp.S3-4.1.86 on 1 January 1970
    J. clin. Path., 23, Suppl. (Roy. Coll. Path.), 4, 86-101 Thrombosis and embolism after injury J Clin Pathol: first published as 10.1136/jcp.s3-4.1.86 on 1 January 1970. Downloaded from S. SEVITT From the Birmingham Accident Hospital Thrombosis is frequent in injured patients. It classified as follows, namely, local thrombosis, takes different forms, and at least one of them, deep vein thrombosis, pulmonary microem- deep vein thrombosis in the lower limbs, is a bolism, glomerular microthrombosis, allied to common cause of morbidity and death through the Schwartzman reaction, occasional cases of embolic detachment. The different kinds may be arterial thrombosis, and rarely, abacterial vege- tative endocarditis. Thrombi form in flowing blood and are layered structures, unlike blood clots which form copyright. in static blood. They contain platelets, fibrin, red cells, and leucocytes, or a variable mixture, the differences depending on size, genesis, age, and venous or arterial location; but whatever the origin, the building blocks of enlarging thrombi are closely packed clumps of platelets with narrow fibrin borders (Fig. 1). Two main pro- http://jcp.bmj.com/ cesses are involved, namely, coagulation and platelet aggregation. These are interlinked and local release of thrombin is probably the key factor; thrombin promotes platelet clumping at a low concentration and fibrin formation at a higher concentration. Further, the release of substances from platelets can set in motion the coagulation on September 30, 2021 by guest. Protected process. Local Thrombosis and Haemostasis Thrombosis is frequent as a direct response to injury. In burned skin, for example, small venous thrombi may become prominent in the subdermis and subcutaneous tissue.
    [Show full text]
  • Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
    How can it be prevented? You can take steps to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). If you're at risk for these conditions: • See your doctor for regular checkups. • Take all medicines as your doctor prescribes. • Get out of bed and move around as soon as possible after surgery or illness (as your doctor recommends). Moving around lowers your chance of developing a blood clot. References: • Exercise your lower leg muscles during Deep Vein Thrombosis: MedlinePlus. (n.d.). long trips. Walking helps prevent blood Retrieved October 18, 2016, from clots from forming. https://medlineplus.gov/deepveinthrombos is.html If you've had DVT or PE before, you can help prevent future blood clots. Follow the steps What Are the Signs and Symptoms of Deep above and: Vein Thrombosis? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from • Take all medicines that your doctor http://www.nhlbi.nih.gov/health/health- prescribes to prevent or treat blood clots topics/topics/dvt/signs • Follow up with your doctor for tests and treatment Who Is at Risk for Deep Vein Thrombosis? - • Use compression stockings as your DEEP NHLBI, NIH. (n.d.). Retrieved October 18, doctor directs to prevent leg swelling 2016, from http://www.nhlbi.nih.gov/health/health- VEIN topics/topics/dvt/atrisk THROMBOSIS How Can Deep Vein Thrombosis Be Prevented? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from (DVT) http://www.nhlbi.nih.gov/health/health- topics/topics/dvt/prevention How Is Deep Vein Thrombosis Treated? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from http://www.nhlbi.nih.gov/health/health- topics/topics/dvt/treatment Trinity Surgery Center What is deep vein Who is at risk? What are the thrombosis (DVT)? The risk factors for deep vein thrombosis symptoms? (DVT) include: Only about half of the people who have DVT A blood clot that forms in a vein deep in the • A history of DVT.
    [Show full text]
  • Major Clinical Considerations for Secondary Hypertension And
    & Experim l e ca n i t in a l l C Journal of Clinical and Experimental C f a o r d l i a o Thevenard et al., J Clin Exp Cardiolog 2018, 9:11 n l o r g u y o Cardiology DOI: 10.4172/2155-9880.1000616 J ISSN: 2155-9880 Review Article Open Access Major Clinical Considerations for Secondary Hypertension and Treatment Challenges: Systematic Review Gabriela Thevenard1, Nathalia Bordin Dal-Prá1 and Idiberto José Zotarelli Filho2* 1Santa Casa de Misericordia Hospital, São Paulo, Brazil 2Department of scientific production, Street Ipiranga, São José do Rio Preto, São Paulo, Brazil *Corresponding author: Idiberto José Zotarelli Filho, Department of scientific production, Street Ipiranga, São José do Rio Preto, São Paulo, Brazil, Tel: +5517981666537; E-mail: [email protected] Received date: October 30, 2018; Accepted date: November 23, 2018; Published date: November 30, 2018 Copyright: ©2018 Thevenard G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Introduction: In this context, secondary arterial hypertension (SH) is defined as an increase in systemic arterial pressure (SAP) due to an identifiable cause. Only 5 to 10% of patients suffering from hypertension have a secondary form, while the vast majorities have essential hypertension. Objective: This study aimed to describe, through a systematic review, the main considerations on secondary hypertension, presenting its clinical data and main causes, as well as presenting the types of treatments according to the literary results.
    [Show full text]
  • How to Document and Code for Hypertensive Diseases in ICD-10 THIS INSTALLMENT in FPM’S ICD-10 SERIES EXPLAINS the GUIDELINES for CODING HYPERTENSION
    How to Document and Code for Hypertensive Diseases in ICD-10 THIS INSTALLMENT IN FPM’S ICD-10 SERIES EXPLAINS THE GUIDELINES FOR CODING HYPERTENSION. Kenneth D. Beckman, MD, MBA, CPE, CPC ecause ICD-10 can be a distressing topic, let’s start or kidney disease. That code is I10, Essential (primary) with some good news: Hypertension has a limited hypertension. number of ICD-10 codes – only nine codes for pri- As in ICD-9, this code includes “high blood pressure” mary hypertension and five codes for secondary but does not include elevated blood pressure without a B hypertension. This makes the task of coding hypertension diagnosis of hypertension (that would be ICD-10 code relatively simple – well, at least compared to some of the R03.0). If a patient has progressed from elevated blood other ICD-10 complexities. pressure to a formal diagnosis of hypertension, a good Another positive change in ICD-10 is that the new documentation practice would be to include the reason for code set drops the previous reference to benign and progressing the formal diagnosis. Similarly, a single mildly malignant hypertension. As physicians, we are well aware elevated blood pressure reading should be coded with the that hypertension is never truly “benign,” and the removal R03.0 until the formal diagnosis is established. of this antiquated term is a welcome improvement in the Although various sources define hypertension slightly lexicon of diseases. differently, the provider should document elevated systolic But, of course, nothing is easy in ICD-10, and there are pressure above 140 or diastolic pressure above 90 with at several things you need to be aware of before we dig into least two readings on separate office visits.
    [Show full text]
  • Deep Vein Thrombosis (DVT)
    Diseases and Conditions Deep vein thrombosis (DVT) By Mayo Clinic Staff Deep vein thrombosis (DVT) occurs when a blood clot (thrombus) forms in one or more of the deep veins in your body, usually in your legs. Deep vein thrombosis can cause leg pain or swelling, but may occur without any symptoms. Deep vein thrombosis can develop if you have certain medical conditions that affect how your blood clots. Deep vein thrombosis can also happen if you don't move for a long time, such as after surgery, following an accident, or when you are confined to a hospital or nursing home bed. Deep vein thrombosis is a serious condition because blood clots in your veins can break loose, travel through your bloodstream and lodge in your lungs, blocking blood flow (pulmonary embolism). Deep vein thrombosis signs and symptoms can include: Swelling in the affected leg. Rarely, there may be swelling in both legs. Pain in your leg. The pain often starts in your calf and can feel like cramping or a soreness. Deep vein thrombosis may sometimes occur without any noticeable symptoms. When to see a doctor If you develop signs or symptoms of deep vein thrombosis, contact your doctor for guidance. If you develop signs or symptoms of a pulmonary embolism — a life-threatening complication of deep vein thrombosis — seek medical attention immediately. The warning signs of a pulmonary embolism include: Unexplained sudden onset of shortness of breath Chest pain or discomfort that worsens when you take a deep breath or when you cough Feeling lightheaded or dizzy, or fainting Rapid pulse Coughing up blood Deep vein thrombosis occurs when a blood clot forms in the veins that are deep in your body, often in your legs.
    [Show full text]